BR112014016661A2 - formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma - Google Patents
formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesmaInfo
- Publication number
- BR112014016661A2 BR112014016661A2 BR112014016661A BR112014016661A BR112014016661A2 BR 112014016661 A2 BR112014016661 A2 BR 112014016661A2 BR 112014016661 A BR112014016661 A BR 112014016661A BR 112014016661 A BR112014016661 A BR 112014016661A BR 112014016661 A2 BR112014016661 A2 BR 112014016661A2
- Authority
- BR
- Brazil
- Prior art keywords
- release formulation
- urination frequency
- subject
- pharmaceutical composition
- effective amount
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 230000036318 urination frequency Effects 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000013268 sustained release Methods 0.000 abstract 3
- 239000012730 sustained-release form Substances 0.000 abstract 3
- 239000000730 antalgic agent Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Power-Operated Mechanisms For Wings (AREA)
- Guiding Agricultural Machines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
resumo formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma métodos e composições para reduzir a freqüência de urinação são revelados. um método compreende administrar a um sujeito com essa necessidade uma quantidade eficaz de uma composição farmacêutica que compreende um agente analgésico formulado em uma formulação de liberação prolongada. outro método compreende administrar a um sujeito com essa necessidade uma quantidade eficaz de uma composição farmacêutica que compreende múltiplos ingredientes ativos formulados para liberação prolongada. ainda um outro método compreende administrar a um sujeito com essa necessidade uma quantidade eficaz de um diurético seguida com outra administração de uma composição farmacêutica que compreende um agente analgésico formulado para liberação prolongada.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/343,332 US20120135050A1 (en) | 2010-07-08 | 2012-01-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US13/424,000 US8236857B2 (en) | 2010-07-08 | 2012-03-19 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US13/487,348 US20120244221A1 (en) | 2010-07-08 | 2012-06-04 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
PCT/US2012/051888 WO2013103390A1 (en) | 2012-01-04 | 2012-08-22 | Extended-release formulation for reducing the frequency of urination and method of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014016661A2 true BR112014016661A2 (pt) | 2017-06-13 |
BR112014016661A8 BR112014016661A8 (pt) | 2017-07-04 |
Family
ID=48745355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014016661A BR112014016661A8 (pt) | 2012-01-04 | 2012-08-22 | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma |
Country Status (13)
Country | Link |
---|---|
US (3) | US8685453B2 (pt) |
JP (4) | JP2015503583A (pt) |
KR (2) | KR20180025993A (pt) |
AU (2) | AU2012363789B2 (pt) |
BR (1) | BR112014016661A8 (pt) |
CA (1) | CA2856677A1 (pt) |
IL (1) | IL232715A0 (pt) |
MX (1) | MX2014008283A (pt) |
MY (1) | MY173582A (pt) |
RU (1) | RU2603471C2 (pt) |
SG (1) | SG11201500407XA (pt) |
WO (1) | WO2013103390A1 (pt) |
ZA (1) | ZA201404606B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
AU2012284039B2 (en) | 2011-07-18 | 2017-03-30 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
US10711230B2 (en) * | 2012-03-30 | 2020-07-14 | Givaudan Sa | N-acyl proline derivatives as food flavoring compounds |
SG11201610383YA (en) * | 2014-06-06 | 2017-02-27 | Wellesley Pharmaceuticals Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
CN107072971A (zh) * | 2014-09-24 | 2017-08-18 | 韦尔斯利医药有限公司 | 用于减轻膀胱痉挛的药学制剂及其使用方法 |
RU2018111401A (ru) * | 2015-09-01 | 2019-10-02 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Составы с отсроченным высвобождением, способы их получения и применения |
RU2018111400A (ru) * | 2015-09-01 | 2019-10-03 | УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения |
CN108430465A (zh) * | 2015-09-30 | 2018-08-21 | 韦尔斯利医药有限公司 | 用于缓解尿频的组合物、其制造方法和用途 |
TW201726114A (zh) * | 2015-11-23 | 2017-08-01 | 魏斯理製藥公司 | 降低排尿頻率之組成物、其製備方法、及其應用 |
JP7229012B2 (ja) * | 2018-12-25 | 2023-02-27 | 小林製薬株式会社 | 内服用医薬組成物 |
JP2019069991A (ja) * | 2018-12-27 | 2019-05-09 | ウェルズリー ファーマスーティカルズ、エルエルシー | 膀胱痙攣を低減するための医薬製剤およびその使用の方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2121346C1 (ru) * | 1991-09-06 | 1998-11-10 | МакНейлэб, Инк. | Композиция, включающая вещество трамадол и ацетаминофен, и способ лечения с ее использованием |
JP4085433B2 (ja) * | 1997-04-11 | 2008-05-14 | 日本新薬株式会社 | 頻尿・尿失禁治療剤 |
US7138393B2 (en) * | 1998-07-24 | 2006-11-21 | Wyeth | Biologically active vasopressin agonist metabolites |
JP3660979B2 (ja) * | 2000-09-05 | 2005-06-15 | 国立大学法人金沢大学 | 夜間頻尿症の治療剤、夜間頻尿症の予防剤 |
RU2193401C1 (ru) * | 2001-04-02 | 2002-11-27 | Аль-Шукри Салман Хасунович | Способ лечения гиперактивности мочевого пузыря |
US20060100195A1 (en) * | 2001-11-19 | 2006-05-11 | Takayuki Maruyama | Remedies for urinary frequency |
PL372395A1 (en) * | 2002-02-19 | 2005-07-25 | Pharmacia Corporation | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence |
WO2004007495A1 (ja) * | 2002-07-11 | 2004-01-22 | Takeda Pharmaceutical Company Limited | ピロロピリジン誘導体およびその用途 |
KR100522239B1 (ko) * | 2002-07-16 | 2005-10-18 | 주식회사 서울제약 | 아세트아미노펜을 함유하는 제어방출성의 경구용 제제 |
US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
US20040054008A1 (en) * | 2002-09-13 | 2004-03-18 | Tohru Araki | Medicament for treatment of nocturia |
DE60319252T2 (de) * | 2002-09-21 | 2009-03-05 | Zhang, Shuyi | Formulierung von acetaminophen und tramadol mit verzögerter freisetzung |
DK1492519T3 (da) * | 2003-03-21 | 2007-03-05 | Dynogen Pharmaceuticals Inc | Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer |
US20040186180A1 (en) * | 2003-03-21 | 2004-09-23 | Gelotte Cathy K. | Non-steroidal anti-inflammatory drug dosing regimen |
US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
DE10356112A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff |
EP1627876A1 (en) * | 2004-08-20 | 2006-02-22 | Ferring B.V. | Heterocyclic condensed compounds useful as antidiuretic agents |
US20060045912A1 (en) * | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
EP1879578A4 (en) * | 2005-03-21 | 2009-05-13 | Dov Pharmaceutical Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE |
WO2006105670A1 (en) * | 2005-04-08 | 2006-10-12 | Neuromed Pharmaceuticals Ltd. | Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain |
JP2009501785A (ja) * | 2005-07-20 | 2009-01-22 | パナセア バイオテック リミテッド | 新規な調節放出性医薬製剤シクロオキシゲナーゼ酵素阻害剤 |
US20080085314A1 (en) * | 2005-07-29 | 2008-04-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
US20080166407A1 (en) | 2005-07-29 | 2008-07-10 | Shalaby Shalaby W | Solid oral formulations for combination therapy |
WO2007072503A2 (en) * | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
US20070237816A1 (en) * | 2006-04-06 | 2007-10-11 | David Finkelstein | Acetaminophen formulation for joint pain relief |
EP2068837A2 (en) | 2006-07-28 | 2009-06-17 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
US20080057122A1 (en) * | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
JP5345620B2 (ja) * | 2007-08-15 | 2013-11-20 | マクニール−ピーピーシー・インコーポレーテツド | 即時放出及び徐放型イブプロフェンの投与法 |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
-
2012
- 2012-08-22 RU RU2014131285/15A patent/RU2603471C2/ru not_active IP Right Cessation
- 2012-08-22 AU AU2012363789A patent/AU2012363789B2/en not_active Ceased
- 2012-08-22 MX MX2014008283A patent/MX2014008283A/es unknown
- 2012-08-22 SG SG11201500407XA patent/SG11201500407XA/en unknown
- 2012-08-22 JP JP2014551234A patent/JP2015503583A/ja active Pending
- 2012-08-22 MY MYPI2014701369A patent/MY173582A/en unknown
- 2012-08-22 KR KR1020187005757A patent/KR20180025993A/ko active IP Right Grant
- 2012-08-22 KR KR1020147018677A patent/KR20140108675A/ko active Application Filing
- 2012-08-22 BR BR112014016661A patent/BR112014016661A8/pt not_active Application Discontinuation
- 2012-08-22 CA CA2856677A patent/CA2856677A1/en not_active Abandoned
- 2012-08-22 WO PCT/US2012/051888 patent/WO2013103390A1/en active Application Filing
-
2013
- 2013-03-20 US US13/847,927 patent/US8685453B2/en not_active Expired - Fee Related
-
2014
- 2014-02-04 US US14/172,649 patent/US20140154320A1/en not_active Abandoned
- 2014-05-20 IL IL232715A patent/IL232715A0/en unknown
- 2014-06-23 ZA ZA2014/04606A patent/ZA201404606B/en unknown
-
2015
- 2015-06-04 US US14/730,934 patent/US20150272968A1/en not_active Abandoned
-
2016
- 2016-09-13 JP JP2016178118A patent/JP2017031172A/ja active Pending
-
2017
- 2017-05-22 AU AU2017203418A patent/AU2017203418B2/en not_active Ceased
-
2018
- 2018-02-02 JP JP2018016869A patent/JP2018087217A/ja active Pending
-
2019
- 2019-11-08 JP JP2019203550A patent/JP2020037575A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018087217A (ja) | 2018-06-07 |
JP2017031172A (ja) | 2017-02-09 |
AU2012363789A2 (en) | 2014-07-24 |
RU2603471C2 (ru) | 2016-11-27 |
AU2012363789A1 (en) | 2014-07-17 |
SG11201500407XA (en) | 2015-03-30 |
JP2015503583A (ja) | 2015-02-02 |
AU2017203418B2 (en) | 2019-01-17 |
US20150272968A1 (en) | 2015-10-01 |
WO2013103390A1 (en) | 2013-07-11 |
AU2017203418A1 (en) | 2017-06-08 |
AU2012363789B2 (en) | 2017-04-13 |
US20140154320A1 (en) | 2014-06-05 |
IL232715A0 (en) | 2014-07-31 |
NZ626619A (en) | 2017-03-31 |
CA2856677A1 (en) | 2013-07-11 |
ZA201404606B (en) | 2015-11-25 |
MY173582A (en) | 2020-02-04 |
RU2014131285A (ru) | 2016-02-20 |
BR112014016661A8 (pt) | 2017-07-04 |
KR20140108675A (ko) | 2014-09-12 |
KR20180025993A (ko) | 2018-03-09 |
NZ721818A (en) | 2017-07-28 |
MX2014008283A (es) | 2015-03-03 |
US20130216620A1 (en) | 2013-08-22 |
JP2020037575A (ja) | 2020-03-12 |
US8685453B2 (en) | 2014-04-01 |
NZ732149A (en) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014016550A2 (pt) | formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma | |
BR112014016661A8 (pt) | formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma | |
BR112012010083B8 (pt) | Composição farmacêutica tópica de liberação sustentada e uso relacionado | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
BR112012023021A2 (pt) | compostos de indazol e seus usos | |
ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
BR112015019657A2 (pt) | composições tópicas e métodos de uso das mesmas | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
BR112015021112A2 (pt) | composições farmacêuticas que compreendem everolimo | |
CL2015002433A1 (es) | Imidazopiridazinas sustituidas | |
MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
IN2014DN10134A (pt) | ||
DOP2015000127A (es) | Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il] benzamida | |
AR087488A1 (es) | Uso de composiciones para retrasar el inicio de la fase catagena del cabello | |
CL2015001368A1 (es) | Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta". | |
BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
ECSP12012332A (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
CO6630144A2 (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
FR2971941B1 (fr) | Compositions pharmaceutiques administrables par voie cutanee et destinees au traitement local de la dermatite atopique canine | |
AR063816A1 (es) | Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion | |
MX352778B (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |